Stocks and Finance

Genzyme

Genzyme 2/8/2012

05:55 : More on Sanofi (SNY) Q4: Income at Genzyme and emerging markets offsets ... - More on Sanofi (SNY) Q4: Income at Genzyme and emerging markets offsets the expiry of patents and the effect of EU austerity. Sanofi expects 2012 business EPS to fall 12%-15% due to patent loss of Plavix and Avapro, but predicts 5% annual ...
Source : seekingalpha-com

Genzyme 1/24/2012

15:44 : Veracyte thyroid test gets boost with Genzyme deal - When biotech drug developer Genzyme Corp. said Friday that it will market a thyroid nodule analysis test, South San Francisco-based Veracyte Inc. got a big boost. Although terms of the deal were not disclosed, Genzyme’s promotion means ...
Source : bizjournals-com

Genzyme 12/22/2011

10:30 : Led by former Genzyme exec, Calif. biotech moves to Cambridge - Inspiration Biopharmaceuticals Inc., a biotechnology company focused on developing treatments for hemophilia, will move to Cambridge, Mass. from Laguna Niguel, Calif. The company named John Butler, former head of rare diseases at Cambridge, Mass.-based ...
Source : bizjournals-com

Genzyme 12/16/2011

14:32 : Former Boston Fed Chief, Genzyme director charged by SEC - Richard F. Syron, a former head of the Boston Federal Reserve Bank -- and current board member of Cambridge biotechnology firm Genzyme Corp. -- is among six former top executives at Fannie Mae and ...
Source : bizjournals-com

Genzyme 11/14/2011

02:09 : Sanofi's Genzyme: progress with relapsing-MS drug - TEL AVIV (MarketWatch) -- Genzyme said on Monday that alemtuzumab, a drug in testing to treat relapsing multiple sclerosis, met its two key endpoints in a Phase III trial. "Relapse rate and [worsening] of disability were significantly reduced" ...
Source : marketwatch-com

Genzyme 7/28/2011

02:15 : Sanofi ups EPS but Genzyme seen missing milestone - PARIS (Reuters) - French drugmaker Sanofi raised its earnings forecast for 2011 now that Genzyme is part of its business, but said the U.S. biotech would likely miss its first milestone fee due to supply constraints of one of its key drugs.
Source : reuters-com

Genzyme 5/26/2011

09:09 : Genzyme to cash out $3.8M in high-flying Abiomed - Genzyme Corp. plans to sell 200,000 of the shares it holds in Abiomed Inc. (Nasdaq: ABMD), according to a regulatory document Genzyme filed on Wednesday - a stake worth $3.8 million at Abiomed's Wednesday closing ...
Source : bizjournals-com

Genzyme 4/4/2011

07:33 : Sanofi-Aventis (SNY) completes its improved $20.1B offer for Genzyme (GENZ - Sanofi-Aventis (SNY) completes its improved $20.1B offer for Genzyme (GENZ) after 84.6% of the U.S. company's stock was tendered. Sanofi-Aventis will now start merging the U.S. biotech's operations ...
Source : seekingalpha-com
06:39 : Sanofi gains control of Genzyme - PARIS (Reuters) - French drugmaker Sanofi-Aventis said it had gained control of Genzyme, with trading in certificates used to help win over shareholders in the U.S. biotech set to start trading later...
Source : reuters-com
01:33 : Sanofi-Aventis completes offer for Genzyme - MADRID (MarketWatch) -- French drugmaker Sanofi-Aventis SA on Monday said it has completed its $74-a-share offer for Genzyme Corp. . Sanofi-Aventis said it has completed its exchange offer for all ...
Source : marketwatch-com
00:32 : Sanofi-Aventis says completes offer for Genzyme - PARIS (Reuters) - French drugmaker Sanofi-Aventis completed its improved $20.1 billion offer for Genzyme, allowing it to begin merging the U.S. biotech firm into its business and add rare diseases to its growth areas.
Source : reuters-com

Genzyme 4/1/2011

16:00 : After Hours: Genzyme, BlackRock shares busy in after-hours - Biotech firm Genzyme Corp. topped actively traded issues Friday evening, marking its exit out of a key U.S. equity index. BlackRock shares also busy as they take Genzyme’s place.
Source : marketwatch-com

Genzyme 3/29/2011

18:12 : IPO Watch: The Alternative Genzyme IPO (SNY, GENZ, GCVRZ, BBH, IBB, FBT) - U.S. stocks finished slightly lower Wednesday, drifting into the red during the final hour of trading as volumes remained lackluster and cautious investors continued to focus on global developments.
Source : 247wallst-com
17:05 : BlackRock to replace Genzyme in S&P 500 index - SAN FRANCISCO (MarketWatch) -- Investment management company BlackRock Inc. will replace Genzyme Corp. in the S&P 500 index after the close of trading on Friday, S&P Indices said late Tuesday. Genzyme ...
Source : marketwatch-com

Genzyme 3/10/2011

04:35 : Genzyme Shares Hit New High Again - Genzyme Corp. (NASDAQ: GENZ) said Monday that its board has unanimously recommended to its shareholders to accept the latest sweetened offer from French drug giant Sanofi-Aventis SA (NYSE: SNY) and to tender their shares ...
Source : ibtimes-com

Genzyme 3/8/2011

11:42 : Genzyme hits new 52-week high in mixed sector - SAN FRANCISCO (MarketWatch) -- Biotech and pharmaceuticals stocks fluctuated between small gains and losses Tuesday as shares of Genzyme Corp. reached a new 52-week high. On Monday, Genzyme's board unanimously recommended that shareholders ...
Source : marketwatch-com
04:47 : Genzyme Shares Hit New High as Board Recommends Sanofi's Revised Offer - Shares of Genzyme Corp. (NASDAQ: GENZ) touched a new 52-week high of $75.90 on Monday. The biotechnology firm's board has unanimously recommended to its shareholders to accept the latest sweetened offer from French drug giant Sanofi ...
Source : ibtimes-com

Genzyme 3/7/2011

14:55 : Genzyme CEO Termeer to leave with about $160 million - NEW YORK (Reuters) - Genzyme Corp Chief Executive Henri Termeer is set to walk away with nearly $160 million when the sale of his company to French drugmaker Sanofi-Aventis is final -- and stands ...
Source : reuters-com
11:36 : Genzyme board recommends Sanofi Aventis offer - SAN FRANCISCO (MarketWatch) -- Genzyme Corp.'s board on Monday unanimously recommended that shareholders accept a $74-a-share offer from Sanofi Aventis SA . The offer also includes one contingent value right for each ...
Source : marketwatch-com
01:45 : Sanofi extends offer for outstanding Genzyme shares - PARIS (Reuters) - French drugmaker Sanofi-Aventis has extended its offer for all outstanding shares of U.S. biotech Genzyme until April 1 from March 16, it said in a statement on Monday.
Source : reuters-com

Genzyme 2/18/2011

23:52 : Genzyme cuts jobs - Genzyme Corp. (Nasdaq: GENZ) said Friday that it is in the process of cutting 170 position — 60 of them already unfilled — as part of a previously announced plan to shed 1,000 jobs. Of the 110 “filled positions” Genzyme is ...
Source : bizjournals-com

Genzyme 2/17/2011

09:34 : Today’s Best Market Rumors (2/17/2011) New Job For Genzyme CEO? - The prices that American consumers pay for goods and services rose a seasonally adjusted 0.4% in January, mainly because of higher gas and grocery expenses,
Source : 247wallst-com

Genzyme 2/16/2011

19:54 : Dealtalk: A walk in the Alps put Genzyme deal on track - BOSTON/PHILADELPHIA (Reuters) - It took the rarefied air of the Swiss Alps to bring together the chief executives of Sanofi-Aventis and Genzyme Corp and pave the way for a $20.1 billion deal.
Source : reuters-com
17:30 : MarketWatch First Take: Sanofi’s big Genzyme hedge - Sanofi-Aventis closed the buyer-seller gap with a pledge to pay full value to Genzyme shareholders upon delivery of an unfinished product, writes Jim Jelter.
Source : marketwatch-com
16:38 : Sanofi-Aventis to buy Genzyme for $20 billion - Sanofi-Aventis is buying specialty drugmaker Genzyme for $20.1 billion, the latest example of a beleaguered pharmaceutical company snapping up high-priced biotech drugs to offset dwindling sales of older, simpler medications ...
Source : usnews-com
12:23 : Moody's may upgrade Genzyme on Sanofi deal - SAN FRANCISCO (MarketWatch) -- Moody's Investors Service on Wednesday placed Genzyme Corp.'s Baa2 senior unsecured ratings under review for possible upgrade. Earlier Wednesday, Sanofi-Aventis SA said it will buy Genzyme ...
Source : marketwatch-com
09:54 : Sanofi-Aventis to buy Genzyme for $20.1B cash - French drug maker Sanofi-Aventis has agreed to buy Genzyme in a sweetened all-cash deal that values the U.S. biotechnology company at $20.1 billion, ...
Source : usatoday-com
09:40 : DealBook: Sanofi Agrees to Buy Genzyme for $20.1 Billion - Sanofi-Aventis said Wednesday that it had agreed to buy the biotech company Genzyme for $74 per share plus an additional sum pegged to performance, with the upfront payment alone worth $20.1 billion.
Source : iht-com
09:20 : NewsWatch: Futures rise after Genzyme deal, Dell results - U.S. stock futures rise, with Genzyme in focus after agreeing to a long-awaited takeover and Dell shares rising on the back of strong quarterly earnings.
Source : marketwatch-com
06:24 : Indications: Futures rise after Genzyme deal, Dell results - U.S. stock futures rise, with Genzyme in focus after agreeing to a long-awaited deal and Dell shares rising on the back of strong quarterly earnings.
Source : marketwatch-com
actualidad Genzyme -
Logo Genzyme


Biotechnology

Pharmaceuticals

Medical Supplies

Medical Equipment

Health Care Providers

Copyright © 2009 Finaperf.com - Exchange rate - Investir - Stock Exchange - Börse - Finanças - Bolsa - Tous droits réservés
Site édité par Yanga.net - Contacts